Codexis, Inc.
Codexis, Inc. (Nasdaq: CDXS) develops engineered enzymes and related technology to improve the manufacture of therapeutics. Its CodeEvolver platform uses directed evolution and computational tools to discover and optimize proteins for specific industrial processes. The company’s ECO Synthesis platform combines… From the company’s description.
Over the twelve months to Jun 30, 2026, Codexis, Inc. reported revenue of $77.68M, up 35.9% from a year earlier, and a net loss of $30.72M. Its operating margin was −35.6%, and operations used $10.40M in cash. In fiscal 2025, it reported revenue of $70.39M, up 18.6% from fiscal 2024, and a net loss of $43.97M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Codexis, Inc. does
In the company’s own words
Codexis, Inc. (Nasdaq: CDXS) develops engineered enzymes and related technology to improve the manufacture of therapeutics. Its CodeEvolver platform uses directed evolution and computational tools to discover and optimize proteins for specific industrial processes. The company’s ECO Synthesis platform combines enzymatic tools and processes for producing RNA interference therapeutics, including small interfering RNA, and provides customers with process development, analytical method development, and non-GMP manufacturing services. Its small-molecule pharmaceutical biocatalysis business supplies engineered enzymes and research and development services to pharmaceutical manufacturers seeking to improve production processes for drug intermediates and active pharmaceutical ingredients. Codexis also licenses its enzyme-engineering platform and supplies enzymes for other molecular biology applications. The company serves pharmaceutical and biotechnology companies, drug developers, and contract development and manufacturing organizations. In 2025, its enzymes were used in manufacturing 18 commercially approved therapeutic drugs, and it sold enzymes for 15 clinical-stage drug candidates. Codexis reported $[not provided] in revenue for fiscal 2025. Major brands include CodeEvolver and ECO Synthesis. Its website is www.codexis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1200375
- SIC
- 2860
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Codexis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Codexis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Codexis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Codexis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Codexis, Inc.'s last four quarterly filings that the numbers alone won't show?”